JP Patent

JP6244497B1 — 選択的ｓ１ｐ１レセプターアゴニストの投与法

Assigned to Actelion Pharmaceuticals Ltd · Expires 2017-12-06 · 8y expired

What this patent protects

本発明は、（Ｒ）−５−［３−クロロ−４−（２，３−ジヒドロキシ−プロポキシ）−ベンゾ［Ｚ］イリデン］−２−（［Ｚ］−プロピルイミノ）−３−ｏ−トリル−チアゾリジン−４−オンの投与法に関する。【選択図】なし

USPTO Abstract

本発明は、（Ｒ）−５−［３−クロロ−４−（２，３−ジヒドロキシ−プロポキシ）−ベンゾ［Ｚ］イリデン］−２−（［Ｚ］−プロピルイミノ）−３−ｏ−トリル−チアゾリジン−４−オンの投与法に関する。【選択図】なし

Drugs covered by this patent

Patent Metadata

Patent number: JP6244497B1
Jurisdiction: JP
Classification: —
Expires: 2017-12-06
Drug substance claim: No
Drug product claim: No
Assignee: Actelion Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.